MART-1 (26-35) human
Need Assistance?
  • US & Canada:
    +
  • UK: +

MART-1 (26-35) human

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

MART-1 (26-35), an immunodominant antigen from melanocyte/melanoma (Melan-A/MART) protein, is amino acid residue 26 to 35 of MART-1 protein.

Category
Peptide Inhibitors
Catalog number
BAT-006173
CAS number
156251-01-3
Molecular Formula
C42H74N10O14
Molecular Weight
943.09
MART-1 (26-35) human
Size Price Stock Quantity
5 mg $298 In stock
IUPAC Name
(4S)-4-amino-5-[[(2S)-1-[[(2S)-1-[[2-[[(2S,3S)-1-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
Synonyms
Melanoma antigen recognized by T-cells 1 (26-35); MART-1(26-35)(A27L) peptide; Melan-A (26-35); H-Glu-Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val-OH; L-alpha-glutamyl-L-alanyl-L-alanyl-glycyl-L-isoleucyl-glycyl-L-isoleucyl-L-leucyl-L-threonyl-L-valine
Appearance
White or Off-white Lyophilized Powder
Purity
98%
Density
1.223±0.06 g/cm3
Boiling Point
1358.4±65.0 °C at 760 Torr
Sequence
EAAGIGILTV
Storage
Store in a cool and dry place and at 2-8°C for short term (days to weeks) or store at -20°C for long term (months to years)
Solubility
Soluble in DMSO, Water
InChI
InChI=1S/C42H74N10O14/c1-12-21(7)32(49-28(54)17-44-35(58)23(9)46-36(59)24(10)47-37(60)26(43)14-15-30(56)57)39(62)45-18-29(55)50-33(22(8)13-2)40(63)48-27(16-19(3)4)38(61)52-34(25(11)53)41(64)51-31(20(5)6)42(65)66/h19-27,31-34,53H,12-18,43H2,1-11H3,(H,44,58)(H,45,62)(H,46,59)(H,47,60)(H,48,63)(H,49,54)(H,50,55)(H,51,64)(H,52,61)(H,56,57)(H,65,66)/t21-,22-,23-,24-,25+,26-,27-,31-,32-,33-,34-/m0/s1
InChI Key
TUIOKRGNEZUFAI-NMIMMQBESA-N
Canonical SMILES
CCC(C)C(C(=O)NCC(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=
1. Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-126(27L)-35
Andrew K Sewell, Emily S J Edwards, Brian M Baker, Marion Tarbe, Kim M Miles, John J Miles, Stéphane Quideau ChemMedChem . 2020 May 6;15(9):799-807. doi: 10.1002/cmdc.202000038.
A click-chemistry-based approach was implemented to prepare peptidomimetics designed in silico and made from aromatic azides and a propargylated GIGI-mimicking platform derived from the altered Melan-A/MART-126(27L)-35antigenic peptide ELAGIGILTV. The CuI-catalyzed Huisgen cycloaddition was carried out on solid support to generate rapidly a first series of peptidomimetics, which were evaluated for their capacity to dock at the interface between the major histocompatibility complex class-I (MHC-I) human leucocyte antigen (HLA)-A2 and T-cell receptors (TCRs). Despite being a weak HLA-A2 ligand, one of these 11 first synthetic compounds bearing a p-nitrobenzyl-triazole side chain was recognized by the receptor proteins of Melan-A/MART-1-specific T-cells. After modification of the N and C termini of this agonist, which was intended to enhance HLA-A2 binding, one of the resulting seven additional compounds triggered significant T-cell responses. Thus, these results highlight the capacity of naturally circulating human TCRs that are specific for the native Melan-A/MART-126-35peptide to cross-react with peptidomimetics bearing organic motifs structurally different from the native central amino acids.
2. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition
Oleg Y Borbulevych, Nicholas P Restifo, Daniel J Powell Jr, Francis K Insaidoo, Brian M Baker, Tiffany K Baxter, Laura A Johnson J Mol Biol . 2007 Oct 5;372(5):1123-36. doi: 10.1016/j.jmb.2007.07.025.
Small structural changes in peptides presented by major histocompatibility complex (MHC) molecules often result in large changes in immunogenicity, supporting the notion that T cell receptors are exquisitely sensitive to antigen structure. Yet there are striking examples of TCR recognition of structurally dissimilar ligands. The resulting unpredictability of how T cells will respond to different or modified antigens impacts both our understanding of the physical bases for TCR specificity as well as efforts to engineer peptides for immunomodulation. In cancer immunotherapy, epitopes and variants derived from the MART-1/Melan-A protein are widely used as clinical vaccines. Two overlapping epitopes spanning amino acid residues 26 through 35 are of particular interest: numerous clinical studies have been performed using variants of the MART-1 26-35 decamer, although only the 27-35 nonamer has been found on the surface of targeted melanoma cells. Here, we show that the 26-35 and 27-35 peptides adopt strikingly different conformations when bound to HLA-A2. Nevertheless, clonally distinct MART-1(26/27-35)-reactive T cells show broad cross-reactivity towards these ligands. Simultaneously, however, many of the cross-reactive T cells remain unable to recognize anchor-modified variants with very subtle structural differences. These dichotomous observations challenge our thinking about how structural information on unligated peptide/MHC complexes should be best used when addressing questions of TCR specificity. Our findings also indicate that caution is warranted in the design of immunotherapeutics based on the MART-1 26/27-35 epitopes, as neither cross-reactivity nor selectivity is predictable based on the analysis of the structures alone.
3. Immunoproteasomes edit tumors, which then escapes immune recognition
Sebastian Joyce Eur J Immunol . 2015 Dec;45(12):3241-5. doi: 10.1002/eji.201546100.
In 1985, John Monaco--the discoverer of LMP-2 and -7, the inducible components of the immunoproteasome--asked his advanced immunology class as to why the MHC region contained not only structural genes, but several others as well, whose functions were then unknown. As we drew a blank, he quipped: perchance because many of the MHC genes are induced by IFN-γ! The ensuing three decades have witnessed the unveiling of the profound fundamental and clinical implications of that classroom tête-à-tête. Amongst its multitudinous effects, IFN-γ induces genes enhancing antigen processing and presentation to T cells; such as those encoding cellular proteases and activators of proteases. In this issue, Keller et al. [Eur. J. Immunol. 2015. 45: 3257-3268] demonstrate that the limited success of MART-1/Melan-A-targeted immunotherapy in melanoma patients could be due to inefficient MART-1(26-35) presentation, owing to the proteolytic activities of IFN-γ-inducible β2i/MECL-1, proteasome activator 28 (PA28), and endoplasmic reticulum-associated aminopeptidase-associated with antigen processing (ERAP). Specifically, whilst β2i and PA28 impede MART-1(26-35) liberation from its precursor protein, ERAP-1 degrades this epitope. Hence, critical to effective cancer immunotherapy is deep knowledge of T-cell-targeted tumor antigens and how cellular proteases generate protective epitope(s) from them, or destroy them.
Online Inquiry
Verification code
Inquiry Basket